skip to main content

Carboplatin Desensitisation — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateGynaecological CancersCarboplatin DesensitisationSCE Medical Oncology

A 60-year-old woman with ovarian cancer on carboplatin develops grade 3 hypersensitivity at cycle 8. Can she receive more platinum?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Carboplatin desensitisation protocol (graded reintroduction in HDU setting) allows safe re-exposure in ~80-90% of cases

Carboplatin hypersensitivity: typically after ≥6 cycles. Desensitisation (graded dose escalation over 4-6 hours in HDU) achieves safe re-exposure ~80-90%. Cisplatin has ~25-50% cross-reactivity.

Reference: Markman et al JCO 2003; ESMO 2024 Ovarian